PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21609353-10 2011 Compared with placebo, metyrapone reduced ACTH efficacy from 11 (6 2-62) to 2 8 (1 5-4 5) nmol/l/min for cortisol (n = 9, P < 0 001), while increasing ACTH efficacy for 11-desoxycortisol from 2 3 (0 9-2 9) to 99 (70-218) nmol/l/min (n = 6, P < 0 01), thus affirming face validity. Metyrapone 23-33 proopiomelanocortin Homo sapiens 42-46 21609353-10 2011 Compared with placebo, metyrapone reduced ACTH efficacy from 11 (6 2-62) to 2 8 (1 5-4 5) nmol/l/min for cortisol (n = 9, P < 0 001), while increasing ACTH efficacy for 11-desoxycortisol from 2 3 (0 9-2 9) to 99 (70-218) nmol/l/min (n = 6, P < 0 01), thus affirming face validity. Metyrapone 23-33 proopiomelanocortin Homo sapiens 154-158 21797928-14 2011 RESULTS: All clinical and biochemical parameters investigated were weakly and non-significantly correlated with the post-metyrapone ACTH, except for the morning serum ACTH (r = 0.68; p <0.001). Metyrapone 121-131 proopiomelanocortin Homo sapiens 132-136 21752886-3 2011 OBJECTIVE: Our objective was to assess the efficacy and safety of combination therapy with mitotane, metyrapone, and ketoconazole in severe ACTH-dependent Cushing"s syndrome. Metyrapone 101-111 proopiomelanocortin Homo sapiens 140-144 17561933-9 2007 Of the two available tests, the correctly performed overnight metyrapone test (with ACTH levels) is safe and better by far. Metyrapone 62-72 proopiomelanocortin Homo sapiens 84-88 22687664-0 2011 Metyrapone: a management option for ectopic ACTH syndrome in small cell lung cancer treated with intravenous etoposide. Metyrapone 0-10 proopiomelanocortin Homo sapiens 44-48 21932593-8 2011 Daily NS dose/ m2 and cumulative NS dose/m2 were significantly (p = 0.03) inversely correlated with the post-metyrapone ACTH (r = -0.42 for both). Metyrapone 109-119 proopiomelanocortin Homo sapiens 120-124 19446401-3 2009 METHOD: Eleven GWV without PTSD, 18 GWV with PTSD and 15 healthy subjects not exposed to the Gulf War theater (non-exposed) underwent the metyrapone stimulation test, which inhibits cortisol synthesis, impairs cortisol-mediated negative feedback inhibition and in turn increases levels of ACTH and 11-deoxycortisol, a cortisol precursor. Metyrapone 138-148 proopiomelanocortin Homo sapiens 289-293 19446401-7 2009 Among GWV, unexplained medical health symptoms (e.g., neurological, musculoskeletal, cardiac, and pulmonary symptoms) and PTSD symptoms were significantly positively associated with the ACTH response to metyrapone. Metyrapone 203-213 proopiomelanocortin Homo sapiens 186-190 19446401-8 2009 CONCLUSION: Gulf War deployment is associated with a substantially lower ACTH response to metyrapone. Metyrapone 90-100 proopiomelanocortin Homo sapiens 73-77 17213295-3 2007 He was started on oral metyrapone for elevated serum cortisol, ACTH, and 24 hour urinary unbound cortisol levels. Metyrapone 23-33 proopiomelanocortin Homo sapiens 63-67 17462829-0 2007 Sex differences in ACTH pulsatility following metyrapone blockade in patients with major depression. Metyrapone 46-56 proopiomelanocortin Homo sapiens 19-23 17220632-3 2007 In the present case, it was demonstrated that metyrapone administration resulted in a significant decrease in the plasma ACTH and serum cortisol levels. Metyrapone 46-56 proopiomelanocortin Homo sapiens 121-125 17220632-7 2007 Interestingly, plasma ACTH as well as serum cortisol levels immediately decreased after metyrapone administration. Metyrapone 88-98 proopiomelanocortin Homo sapiens 22-26 17446657-6 2007 As the dose of metyrapone was increased, plasma ACTH levels gradually increased. Metyrapone 15-25 proopiomelanocortin Homo sapiens 48-52 17336940-10 2007 CONCLUSIONS: Similar to our previous findings in men, the ACTH and sleep electroencephalogram response to metyrapone is attenuated in women with PTSD. Metyrapone 106-116 proopiomelanocortin Homo sapiens 58-62 16824495-0 2006 Sex differences in the ACTH response to 24H metyrapone in depression. Metyrapone 44-54 proopiomelanocortin Homo sapiens 23-27 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 81-91 proopiomelanocortin Homo sapiens 241-245 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 81-91 proopiomelanocortin Homo sapiens 439-443 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 260-270 proopiomelanocortin Homo sapiens 241-245 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 260-270 proopiomelanocortin Homo sapiens 439-443 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 260-270 proopiomelanocortin Homo sapiens 241-245 16891571-6 2006 The results demonstrate: a) decreased delta sleep in male subjects with PTSD; b) metyrapone administration resulted in an activation of the sleep EEG and a robust decrease in quantitative delta sleep; c) the sleep and endocrine (increase in ACTH) responses to metyrapone were significantly decreased in PTSD in two different study samples; and d) the metyrapone-related disruption to sleep in both samples was predicted by the increase in ACTH measured the following morning. Metyrapone 260-270 proopiomelanocortin Homo sapiens 439-443 12803233-12 2003 Eleven months after liver transplantation, she was again treated with octreotide and, 16 months after, with metyrapone, both of which were effective in reducing ACTH and cortisol levels, respectively, until she died of acute respiratory failure. Metyrapone 108-118 proopiomelanocortin Homo sapiens 161-165 16006722-5 2005 Plasma ACTH levels were increased by corticotropin releasing hormone and metyrapone, while low-dose dexamethasone suppressed cortisol secretion. Metyrapone 73-83 proopiomelanocortin Homo sapiens 7-11 15163445-2 2004 Significant treatment effects of both metyrapone and the combination of dexamethasone and metyrapone were observed for adrenocorticotropic hormone (ACTH), 11-deoxycortisol (11-DOC) and cortisol, but no differences between patients and comparison subjects emerged. Metyrapone 38-48 proopiomelanocortin Homo sapiens 119-146 15163445-2 2004 Significant treatment effects of both metyrapone and the combination of dexamethasone and metyrapone were observed for adrenocorticotropic hormone (ACTH), 11-deoxycortisol (11-DOC) and cortisol, but no differences between patients and comparison subjects emerged. Metyrapone 38-48 proopiomelanocortin Homo sapiens 148-152 15163445-2 2004 Significant treatment effects of both metyrapone and the combination of dexamethasone and metyrapone were observed for adrenocorticotropic hormone (ACTH), 11-deoxycortisol (11-DOC) and cortisol, but no differences between patients and comparison subjects emerged. Metyrapone 90-100 proopiomelanocortin Homo sapiens 119-146 15163445-2 2004 Significant treatment effects of both metyrapone and the combination of dexamethasone and metyrapone were observed for adrenocorticotropic hormone (ACTH), 11-deoxycortisol (11-DOC) and cortisol, but no differences between patients and comparison subjects emerged. Metyrapone 90-100 proopiomelanocortin Homo sapiens 148-152 16303845-9 2006 In response to ACTH, significant increases in the DHEA/cortisol ratio (174 +/- 48 vs. 3 +/- 3, P = 0.008) were seen in the metyrapone group compared with placebo. Metyrapone 123-133 proopiomelanocortin Homo sapiens 15-19 16001448-6 2005 As expected, CO2 increased measures of anxiety, and metyrapone lowered cortisol and increased ACTH levels. Metyrapone 52-62 proopiomelanocortin Homo sapiens 94-98 15219644-8 2004 As a group, the depressed women demonstrated significantly increased ACTH secretion compared to control women before the onset of treatment, during the metyrapone challenge. Metyrapone 152-162 proopiomelanocortin Homo sapiens 69-73 15291697-0 2004 Metyrapone for delirium due to Cushing"s syndrome induced by occult ectopic adrenocorticotropic hormone secretion. Metyrapone 0-10 proopiomelanocortin Homo sapiens 76-103 12799616-11 2003 PTSD subjects had a significantly decreased ACTH response to metyrapone compared to controls. Metyrapone 61-71 proopiomelanocortin Homo sapiens 44-48 10681636-3 1999 Of 38 given high-dose ACTH, 20 had normal responses to metyrapone and to high-dose ACTH. Metyrapone 55-65 proopiomelanocortin Homo sapiens 22-26 11207645-0 2001 Recurrent ACTH-independent Cushing"s syndrome in multiple pregnancies and its treatment with metyrapone. Metyrapone 93-103 proopiomelanocortin Homo sapiens 10-14 11158007-1 2001 We have previously shown that when tested in the morning, older men and women, pretreated with metyrapone to block endogenous cortisol synthesis, exhibit delayed suppression of plasma ACTH in response to cortisol infusion. Metyrapone 95-105 proopiomelanocortin Homo sapiens 184-188 10971447-11 2000 CONCLUSIONS: The overnight metyrapone test identified more patients with possible ACTH deficiency than the insulin hypoglycaemia test. Metyrapone 27-37 proopiomelanocortin Homo sapiens 82-86 10971447-12 2000 Further follow-up of these patients is required before a final judgement can be made as to whether more subtle but clinically relevant ACTH deficiency can be detected by the metyrapone test. Metyrapone 174-184 proopiomelanocortin Homo sapiens 135-139 10931104-10 2000 The 12 patients who failed the metyrapone test had a significantly impaired cortisol response to low dose ACTH stimulation at all time points when compared with both the control group and the pituitary patients with a normal response to metyrapone (P < 0.001). Metyrapone 31-41 proopiomelanocortin Homo sapiens 106-110 10101722-5 1999 Attenuation of corticosteroid feedback with metyrapone results in significant increases in circulating ACTH, and in older monkeys increases plasma HVA. Metyrapone 44-54 proopiomelanocortin Homo sapiens 103-107 10681636-6 1999 All 24 with low metyrapone response had low or borderline response to low-dose ACTH. Metyrapone 16-26 proopiomelanocortin Homo sapiens 79-83 7735369-8 1994 The measurement of ACTH using the HS IRMA assay, increases the sensitivity of the metyrapone test in detecting patients with partial ACTH deficiency. Metyrapone 82-92 proopiomelanocortin Homo sapiens 19-23 9231057-0 1997 Metyrapone pre-treated inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing"s syndrome. Metyrapone 0-10 proopiomelanocortin Homo sapiens 89-93 9231057-3 1997 We hypothesized that, given the unavailability of CRF in Australia, stimulation of ACTH secretion from tumorous corticotrophs with metyrapone treatment before IPSS may be useful. Metyrapone 131-141 proopiomelanocortin Homo sapiens 83-87 9231057-19 1997 CONCLUSIONS: Metyrapone pre-treated inferior petrosal sinus sampling is safe, and appears to induce high ACTH output from pituitary corticotroph adenomas. Metyrapone 13-23 proopiomelanocortin Homo sapiens 105-109 9258806-6 1997 ACTH levels were undetectable both in baseline conditions and following CRH or metyrapone. Metyrapone 79-89 proopiomelanocortin Homo sapiens 0-4 9152616-4 1997 After the administration of metyrapone in one case, urinary excretion of 17-hydroxycorticosteroid (17-OHCS) significantly increased, although the plasma ACTH level did not respond. Metyrapone 28-38 proopiomelanocortin Homo sapiens 153-157 8849565-2 1996 We report a patient who maintained a normal response to exogenous ACTH stimulation despite symptomatic chronic ACTH deficiency proven by the insulin tolerance and overnight metyrapone tests. Metyrapone 173-183 proopiomelanocortin Homo sapiens 66-70 8849565-2 1996 We report a patient who maintained a normal response to exogenous ACTH stimulation despite symptomatic chronic ACTH deficiency proven by the insulin tolerance and overnight metyrapone tests. Metyrapone 173-183 proopiomelanocortin Homo sapiens 111-115 8778898-4 1996 In the present study, we examined ACTH release from the pituitary gland in PTSD following the administration of metyrapone. Metyrapone 112-122 proopiomelanocortin Homo sapiens 34-38 8778898-5 1996 Metyrapone resulted in a significantly greater increase of ACTH and 11-deoxycortisol in combat veterans with PTSD (n = 11) compared with normal male volunteers (n = 8). Metyrapone 0-10 proopiomelanocortin Homo sapiens 59-63 8539309-6 1995 Metyrapone administration resulted in a significant decrease in cortisol levels and a significant increase in ACTH and 11-desoxycortisol levels. Metyrapone 0-10 proopiomelanocortin Homo sapiens 110-114 8582096-4 1995 Sodium valproate (SV) inhibits ACTH release in response to CRH, metyrapone and substance P. Metyrapone 64-74 proopiomelanocortin Homo sapiens 31-35 7893592-7 1994 The Rs were below 0.50 for post metyrapone levels of plasma 11-deoxycortisol, ACTH, LPH and beta-endorphin. Metyrapone 32-42 proopiomelanocortin Homo sapiens 92-106 7962332-9 1994 The preservation of ACTH and GH responses to metyrapone and arginine, respectively, suggests adequate pituitary functional reserve in IDDM patients in strict glycemic control in response to nonhypoglycemic stimuli. Metyrapone 45-55 proopiomelanocortin Homo sapiens 20-31 7735369-8 1994 The measurement of ACTH using the HS IRMA assay, increases the sensitivity of the metyrapone test in detecting patients with partial ACTH deficiency. Metyrapone 82-92 proopiomelanocortin Homo sapiens 133-137 8005206-6 1994 RESULTS: In patients with pituitary disease not requiring hydrocortisone substitution (n = 70), the ACTH response in the metyrapone test was subnormal in 47 cases (< 33 pmol/L), the comp. Metyrapone 121-131 proopiomelanocortin Homo sapiens 100-104 8042820-1 1994 OBJECTIVE: To develop criteria for interpreting results of the metyrapone test for the differential diagnosis of the adrenocorticotropin (ACTH)-dependent Cushing syndrome and to compare its diagnostic accuracy with that of the high-dose dexamethasone suppression test. Metyrapone 63-73 proopiomelanocortin Homo sapiens 138-142 8074133-7 1994 In 11 patients who had a normal metyrapone test, the plasma ACTH level increased from 6 +/- 1 pmol/L at baseline to 11 +/- 2 pmol/L 30 minutes after naloxone administration. Metyrapone 32-42 proopiomelanocortin Homo sapiens 60-64 8080346-7 1994 However, in contrast to normal controls treated with metyrapone, metyrapone-treated depressed patients demonstrated rebound corticotroph secretion, particularly between 7:30 and 10 PM (P = .036 for patients vs normal controls for beta-endorphin secretion from 4:30 to 10 PM). Metyrapone 65-75 proopiomelanocortin Homo sapiens 230-244 8013141-14 1994 In only one patient was an abnormal cortisol response to ACTH associated with a normal response to metyrapone. Metyrapone 99-109 proopiomelanocortin Homo sapiens 57-61 8005206-9 1994 S with an ACTH-cortisol dose-response curve obtained in normal subjects shows that subnormal ACTH responses after metyrapone in the range between 13 and 33 pmol/L still generate normal comp. Metyrapone 114-124 proopiomelanocortin Homo sapiens 10-14 8005206-9 1994 S with an ACTH-cortisol dose-response curve obtained in normal subjects shows that subnormal ACTH responses after metyrapone in the range between 13 and 33 pmol/L still generate normal comp. Metyrapone 114-124 proopiomelanocortin Homo sapiens 93-97 8005206-12 1994 CONCLUSIONS: Measuring plasma ACTH in the scope of the metyrapone test makes the test more sensitive to detect secondary adrenal insufficiency than with steroid measurements alone. Metyrapone 55-65 proopiomelanocortin Homo sapiens 30-34 8239397-7 1993 ACTH production is increased (positive dexamethasone suppression test and provocative metopirone and CRH tests) as a result of a pituitary adenoma which should be looked for by magnetic resonance imaging and whose removal ensures recovery in 50% of cases. Metyrapone 86-96 proopiomelanocortin Homo sapiens 0-4 8222300-0 1993 ACTH-independent Cushing"s syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Metyrapone 130-140 proopiomelanocortin Homo sapiens 0-4 1335555-3 1992 We tested these hypotheses by examining ACTH responses to metyrapone, an 11 beta-hydroxylase inhibitor which blocks the formation of cortisol, followed by CRH-41 in 15 severely depressed in-patients diagnosed according to DSM-IIIR criteria. Metyrapone 58-68 proopiomelanocortin Homo sapiens 40-44 1291336-7 1992 Administration of metyrapone raised both urinary 17-OHCS and plasma ACTH levels. Metyrapone 18-28 proopiomelanocortin Homo sapiens 68-72 1490094-0 1992 Beta-endorphin responses to metyrapone and dexamethasone in depressed patients. Metyrapone 28-38 proopiomelanocortin Homo sapiens 0-14 1490094-3 1992 Depressed patients displayed significantly lower beta-endorphin plasma levels in baseline conditions, after the single dose metyrapone test, and after the dexamethasone suppression test. Metyrapone 124-134 proopiomelanocortin Homo sapiens 49-63 8384536-2 1993 We undertook the present study to evaluate the effect of the chronic excess of ACTH, or the short-term excess of ACTH due to metyrapone, on 19-hydroxyandrostenedione secretion in patients with Cushing"s disease. Metyrapone 125-135 proopiomelanocortin Homo sapiens 113-117 8384536-9 1993 CONCLUSIONS: These data indicate that plasma levels of 19-hydroxyandrostenedione in patients with Cushing"s disease are elevated due to chronic ACTH excess, and that metyrapone can inhibit 19-hydroxylation in humans. Metyrapone 166-176 proopiomelanocortin Homo sapiens 144-148 1471455-4 1992 ACTH levels remained high during the 3 h following the end of metyrapone infusion. Metyrapone 62-72 proopiomelanocortin Homo sapiens 0-4 1335555-6 1992 Metyrapone 750 mg was given 4-hourly for 24 h and samples were taken for cortisol and ACTH. Metyrapone 0-10 proopiomelanocortin Homo sapiens 86-90 1335555-8 1992 However, we found exaggerated rises in ACTH amongst the nonsuppressors, as compared to the suppressors and the control group, after metyrapone. Metyrapone 132-142 proopiomelanocortin Homo sapiens 39-43 1336651-6 1992 Dexamethasone suppressibility and the stimulatory effect of metyrapone on ACTH secretion were less in MNH than in DH subjects, suggesting a greater degree of adrenal autonomy in the former. Metyrapone 60-70 proopiomelanocortin Homo sapiens 74-78 1967019-0 1990 Effects of metyrapone and dexamethasone on pro-gamma-MSH and ACTH levels in depressed patients. Metyrapone 11-21 proopiomelanocortin Homo sapiens 47-56 1776645-3 1991 Metyrapone test confirmed ACTH deficiency as a contributing factor to the ketotic hypoglycemia. Metyrapone 0-10 proopiomelanocortin Homo sapiens 26-30 1653782-8 1991 However, ACTH was measured 1) just before operation when the patient was receiving treatment with metyrapone, and 2) postoperatively when the patient was receiving steroid replacement only, and on these occasions ACTH levels were lower than during the initial investigations. Metyrapone 98-108 proopiomelanocortin Homo sapiens 9-13 1664784-6 1991 In metopirone-injected eels, one third of the animals showed an increased immunostaining in perikarya and a dense network of immunoreactive fibers, suggesting that ACTH synthesis was increased. Metyrapone 3-13 proopiomelanocortin Homo sapiens 164-168 1657460-4 1991 MEASUREMENTS: The acute response to metyrapone was assessed by measuring cortisol, 11-desoxycortisol and ACTH at 0, 1, 2, 3, 4 hours after a test dose of 750 mg of metyrapone. Metyrapone 36-46 proopiomelanocortin Homo sapiens 105-109 1656409-4 1991 Responses to metyrapone and inhibition of ACTH and cortisol hypersecretion after high dose dexamethasone during active phases of the disease favored a central origin of ACTH hypersecretion, confirmed by simultaneous bilateral venous sampling of the sinus petrosus inferior. Metyrapone 13-23 proopiomelanocortin Homo sapiens 169-173 1967019-0 1990 Effects of metyrapone and dexamethasone on pro-gamma-MSH and ACTH levels in depressed patients. Metyrapone 11-21 proopiomelanocortin Homo sapiens 61-65 1967019-5 1990 After single-dose metyrapone stimulation, both hormones increased, but pro-gamma-MSH was significantly higher in control subjects than in depressives. Metyrapone 18-28 proopiomelanocortin Homo sapiens 75-84 2177207-7 1990 In the metyrapone test, there was an increase of less than or equal to 3-fold in 11-deoxycortisol at 24 hours in patients with ectopic ACTH; the increase was greater than 3-fold in all but one of the patients with Cushing"s disease. Metyrapone 7-17 proopiomelanocortin Homo sapiens 135-139 2537333-7 1989 There was an exaggerated rise in both the first and second peaks of the plasma ACTH response to oCRH in the metyrapone-treated men. Metyrapone 108-118 proopiomelanocortin Homo sapiens 79-83 2170484-0 1990 Effects of metyrapone and dexamethasone upon pro-gamma-MSH plasma levels in depressed patients and healthy controls. Metyrapone 11-21 proopiomelanocortin Homo sapiens 49-58 2170484-5 1990 After single-dose metyrapone stimulation, both hormones increased, but pro-gamma-MSH was significantly higher in control subjects than in depressives. Metyrapone 18-28 proopiomelanocortin Homo sapiens 75-84 2155255-2 1990 The administration of 4.5 g metyrapone (750 mg, orally, every 4 h) resulted in a decrease in basal (pre-CRH) plasma cortisol levels and an increase in basal plasma ACTH levels in both normal subjects and Cushing"s patients. Metyrapone 28-38 proopiomelanocortin Homo sapiens 164-168 2155255-3 1990 The pretreatment with metyrapone significantly blunted the increase in plasma cortisol levels and markedly enhanced ACTH secretion after iv injection of 100 micrograms human CRH. Metyrapone 22-32 proopiomelanocortin Homo sapiens 116-120 2155255-4 1990 The peak ACTH levels during CRH test before and after metyrapone administration were 8 +/- 1 and 58 +/- 8 pmol/L, respectively, in normal subjects (P less than 0.01) and 26 +/- 5 and 50 +/- 11 pmol/L, respectively, in Cushing"s patients (P less than 0.05). Metyrapone 54-64 proopiomelanocortin Homo sapiens 9-13 2174517-0 1990 Metyrapone effects on beta-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man. Metyrapone 0-10 proopiomelanocortin Homo sapiens 22-36 2174517-0 1990 Metyrapone effects on beta-endorphin, ACTH and cortisol levels after chronic opiate receptor stimulation in man. Metyrapone 0-10 proopiomelanocortin Homo sapiens 38-42 2174517-4 1990 The response of beta-endorphin and ACTH to metyrapone administration was significantly blunted in addicts (p less than 0.01). Metyrapone 43-53 proopiomelanocortin Homo sapiens 16-30 2174517-4 1990 The response of beta-endorphin and ACTH to metyrapone administration was significantly blunted in addicts (p less than 0.01). Metyrapone 43-53 proopiomelanocortin Homo sapiens 35-39 1966779-0 1990 Beta-lipotropin/adrenocorticotropic hormone responses to corticotropin releasing hormone, hypoglycemia, metyrapone and dexamethasone in normal human subjects. Metyrapone 104-114 proopiomelanocortin Homo sapiens 16-43 1966779-10 1990 The greater efficacy of metyrapone treatment in elevating ACTH and beta-LPH levels is most likely mediated by sustained reduction in cortisol production and interruption of the rapid steroid feedback on the pituitary. Metyrapone 24-34 proopiomelanocortin Homo sapiens 58-62 1966779-10 1990 The greater efficacy of metyrapone treatment in elevating ACTH and beta-LPH levels is most likely mediated by sustained reduction in cortisol production and interruption of the rapid steroid feedback on the pituitary. Metyrapone 24-34 proopiomelanocortin Homo sapiens 67-75 2164530-10 1990 The ACTH peak levels after ovine CRH increased after metyrapone administration. Metyrapone 53-63 proopiomelanocortin Homo sapiens 4-8 2537333-11 1989 Despite the greater oCRH-induced release of pituitary ACTH in the metyrapone-treated men, the magnitude of their next morning"s circadian plasma ACTH peak was similar to that after they received placebo oCRH. Metyrapone 66-76 proopiomelanocortin Homo sapiens 54-58 2852510-5 1988 ACTH responses, assessed as areas-under-time-course-curves, were: in normal controls, 6.8 +/- 2.4 (SD) pg/ml/min x 10(3); in unmedicated patients, 2.6 +/- 1.1 pg/ml/min x 10(3); and in metyrapone pretreated patients, 9.0 +/- 6.7 pg/ml/min x 10(3). Metyrapone 185-195 proopiomelanocortin Homo sapiens 0-4 2852510-7 1988 In contrast, this blunting was completely avoided after metyrapone pretreatment, which resulted in net ACTH responses that were indistinguishable from those of the controls. Metyrapone 56-66 proopiomelanocortin Homo sapiens 103-107 3026691-10 1987 ACTH concentrations are between 60 and 330 ng/l, 8-10.5 h after metyrapone (2 g orally at 2300 h), between 140 and 320 ng/l, 30-60 min after insulin-induced hypoglycaemia, and less than 4 ng/l, 8 h after dexamethasone (1.5 mg orally at 2300 h). Metyrapone 64-74 proopiomelanocortin Homo sapiens 0-4 2839946-6 1988 The ACTH and the ACTH/cortisol elevations elicited by metyrapone (35 mg/kg body weight infused over 4 h), and by CRH (1 microgram/kg body weight, iv), respectively, normal before treatment, were significantly impaired (P less than 0.05, less than 0.01) during antiepileptic therapy. Metyrapone 54-64 proopiomelanocortin Homo sapiens 17-21 2820688-0 1987 [Adrenostatic treatment of ACTH-dependent Cushing syndrome using metyrapone and aminoglutethimide]. Metyrapone 65-75 proopiomelanocortin Homo sapiens 27-31 2821448-3 1987 However, the source of ACTH seemed to be autonomous as she demonstrated abnormal feedback control, with lack of response to metyrapone and high coses of dexamethasone. Metyrapone 124-134 proopiomelanocortin Homo sapiens 23-27 2840823-0 1988 Ectopic ACTH syndrome caused by a bronchial carcinoid tumor responsive to dexamethasone, metyrapone, and corticotropin-releasing factor. Metyrapone 89-99 proopiomelanocortin Homo sapiens 8-12 2847889-3 1988 Addition of sodium valproate to metyrapone produced a further reduction in these values in five of six patients with a reduction in plasma ACTH in three of five patients who had dexamethasone-suppressible disease. Metyrapone 32-42 proopiomelanocortin Homo sapiens 139-143 2842388-0 1988 Plasma pro-opiomelanocortin fragments and adrenal steroids following administration of metyrapone to normal and hirsute women. Metyrapone 87-97 proopiomelanocortin Homo sapiens 7-27 2842388-8 1988 Following treatment with dexamethasone there was more profound suppression of the 16K, beta-endorphin and h-lipotropin responses to metyrapone stimulation, than of the ACTH response, as indicated by decreased POMC-fragment/ACTH ratios; this parallels the dissociation of cortisol from androgens in hirsute patients under similar conditions. Metyrapone 132-142 proopiomelanocortin Homo sapiens 87-118 2823973-0 1987 Oxytocin reduces metyrapone-induced ACTH secretion in human subjects. Metyrapone 17-27 proopiomelanocortin Homo sapiens 36-40 2823973-3 1987 Metyrapone, a blocker of cortisol secretion, was given to enhance ACTH release. Metyrapone 0-10 proopiomelanocortin Homo sapiens 66-70 2823973-4 1987 This experimental model was chosen because metyrapone-induced ACTH activation depends on diminution of the negative feed-back of cortisol, which is an important physiological mechanism in the control of ACTH secretion. Metyrapone 43-53 proopiomelanocortin Homo sapiens 62-66 2823973-4 1987 This experimental model was chosen because metyrapone-induced ACTH activation depends on diminution of the negative feed-back of cortisol, which is an important physiological mechanism in the control of ACTH secretion. Metyrapone 43-53 proopiomelanocortin Homo sapiens 203-207 2823973-5 1987 A striking decline in plasma cortisol levels and a 10-fold rise in the mean plasma ACTH concentration was observed within 20 h after the beginning of metyrapone treatment (750 mg orally every 4 h). Metyrapone 150-160 proopiomelanocortin Homo sapiens 83-87 2823973-7 1987 bolus plus 4 IU infused in 2 h) significantly reduced the metyrapone-induced plasma ACTH rise. Metyrapone 58-68 proopiomelanocortin Homo sapiens 84-88 3525603-4 1986 However, while plasma ACTH increased during metyrapone administration and decreased during administration of high dose of dexamethasone, plasma CRH levels did not change, suggesting a direct pituitary response to these testing maneuvers. Metyrapone 44-54 proopiomelanocortin Homo sapiens 22-26 3538739-7 1986 Plasma ACTH was suppressed, even after injection of CRH, during insulin-induced hypoglycaemia and after metyrapone administration, which led to a large fall in plasma cortisol but to a subnormal rise of plasma 11-deoxy-cortisol. Metyrapone 104-114 proopiomelanocortin Homo sapiens 7-11 3038704-1 1986 The short, overnight, metyrapone test with plasma ACTH and beta-endorphin (beta-EP) determination has been performed in patients with migraine, other forms of headache, and healthy volunteers. Metyrapone 22-32 proopiomelanocortin Homo sapiens 75-82 3038704-2 1986 A rise in plasma ACTH and beta-EP after metyrapone occurred in all investigated subjects. Metyrapone 40-50 proopiomelanocortin Homo sapiens 17-21 3038704-2 1986 A rise in plasma ACTH and beta-EP after metyrapone occurred in all investigated subjects. Metyrapone 40-50 proopiomelanocortin Homo sapiens 26-33 3009524-8 1986 The response to metyrapone showed a rise of serum 11-deoxycortisol to 25.6 micrograms/dl and of ACTH to 169.5 pg/ml. Metyrapone 16-26 proopiomelanocortin Homo sapiens 96-100 6326013-7 1984 Overnight administration of metyrapone to polycystic ovary syndrome patients resulted in rises of beta-endorphin and gamma 3-melanocyte stimulating hormone. Metyrapone 28-38 proopiomelanocortin Homo sapiens 98-112 2997256-0 1985 Dermorphin reduces the metyrapone-evoked release of adrenocorticotropin, beta-endorphin, and beta-lipotropin in man. Metyrapone 23-33 proopiomelanocortin Homo sapiens 73-87 2997256-2 1985 Six normal men were treated with oral metyrapone to stimulate the secretion of ACTH, beta-lipotropin, and beta-endorphin. Metyrapone 38-48 proopiomelanocortin Homo sapiens 79-83 2997256-2 1985 Six normal men were treated with oral metyrapone to stimulate the secretion of ACTH, beta-lipotropin, and beta-endorphin. Metyrapone 38-48 proopiomelanocortin Homo sapiens 106-120 3898689-6 1985 In another patient with adrenocortical cancer, and in 2 with the ectopic ACTH syndrome, the cortisol excretion was significantly reduced by the combination of metyrapone and aminoglutethimide but no obvious clinical improvement was observed. Metyrapone 159-169 proopiomelanocortin Homo sapiens 73-77 2993405-0 1985 Metyrapone: an agent for melatonin as well as ACTH and cortisol secretion. Metyrapone 0-10 proopiomelanocortin Homo sapiens 46-50 2993405-6 1985 A second finding was depressed serum melatonin the night after the test in the subjects with the most marked ACTH-cortisol response following the metyrapone-test indicating suppression of melatonin secretion when ACTH-cortisol secretions were increased. Metyrapone 146-156 proopiomelanocortin Homo sapiens 109-113 2993405-6 1985 A second finding was depressed serum melatonin the night after the test in the subjects with the most marked ACTH-cortisol response following the metyrapone-test indicating suppression of melatonin secretion when ACTH-cortisol secretions were increased. Metyrapone 146-156 proopiomelanocortin Homo sapiens 213-217 2993405-8 1985 Thus, it is shown that the metyrapone-induced cortisol inhibition stimulates both ACTH and melatonin secretion, while high ACTH and cortisol levels are accompanied by reduced S-melatonin levels. Metyrapone 27-37 proopiomelanocortin Homo sapiens 82-86 2993405-8 1985 Thus, it is shown that the metyrapone-induced cortisol inhibition stimulates both ACTH and melatonin secretion, while high ACTH and cortisol levels are accompanied by reduced S-melatonin levels. Metyrapone 27-37 proopiomelanocortin Homo sapiens 123-127 3022521-3 1986 For the diagnosis of secondary adrenal failure, plasma ACTH, cortisol and 11-desoxycortisol response to a single midnight dose of metyrapone (1.2 g/m2 = 30 mg/kg) discriminates between a normal (morning ACTH above 100 ng/l), diminished (morning ACTH detectable, but below 100 ng/l), and an absent (ACTH below 20 - 40 ng/l) ACTH reserve. Metyrapone 130-140 proopiomelanocortin Homo sapiens 55-59 3022521-3 1986 For the diagnosis of secondary adrenal failure, plasma ACTH, cortisol and 11-desoxycortisol response to a single midnight dose of metyrapone (1.2 g/m2 = 30 mg/kg) discriminates between a normal (morning ACTH above 100 ng/l), diminished (morning ACTH detectable, but below 100 ng/l), and an absent (ACTH below 20 - 40 ng/l) ACTH reserve. Metyrapone 130-140 proopiomelanocortin Homo sapiens 203-207 3022521-3 1986 For the diagnosis of secondary adrenal failure, plasma ACTH, cortisol and 11-desoxycortisol response to a single midnight dose of metyrapone (1.2 g/m2 = 30 mg/kg) discriminates between a normal (morning ACTH above 100 ng/l), diminished (morning ACTH detectable, but below 100 ng/l), and an absent (ACTH below 20 - 40 ng/l) ACTH reserve. Metyrapone 130-140 proopiomelanocortin Homo sapiens 203-207 3022521-3 1986 For the diagnosis of secondary adrenal failure, plasma ACTH, cortisol and 11-desoxycortisol response to a single midnight dose of metyrapone (1.2 g/m2 = 30 mg/kg) discriminates between a normal (morning ACTH above 100 ng/l), diminished (morning ACTH detectable, but below 100 ng/l), and an absent (ACTH below 20 - 40 ng/l) ACTH reserve. Metyrapone 130-140 proopiomelanocortin Homo sapiens 203-207 3022521-3 1986 For the diagnosis of secondary adrenal failure, plasma ACTH, cortisol and 11-desoxycortisol response to a single midnight dose of metyrapone (1.2 g/m2 = 30 mg/kg) discriminates between a normal (morning ACTH above 100 ng/l), diminished (morning ACTH detectable, but below 100 ng/l), and an absent (ACTH below 20 - 40 ng/l) ACTH reserve. Metyrapone 130-140 proopiomelanocortin Homo sapiens 203-207 2997256-3 1985 In these subjects, significant suppression of metyrapone-evoked release of ACTH and related peptides occurred during D infusion (5.5 micrograms/kg X min for 30 min) compared with that during saline infusion. Metyrapone 46-56 proopiomelanocortin Homo sapiens 75-79 6099512-0 1984 ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Metyrapone 46-56 proopiomelanocortin Homo sapiens 19-33 6326444-6 1984 The absence of beta-LPH response to MTP in these 8 patients was in good agreement with the diagnosis of ACTH insufficiency because in 7 of them the cortisol response to insulin induced hypoglycaemia was also insufficient. Metyrapone 36-39 proopiomelanocortin Homo sapiens 15-23 6326444-10 1984 In the 4 patients with Cushing"s disease, MTP administration resulted in a dramatic increase of beta-LPH concentration. Metyrapone 42-45 proopiomelanocortin Homo sapiens 96-104 6326444-0 1984 The value of beta-lipotrophin measurement during the short metyrapone test in patients with pituitary diseases and in Cushing"s syndrome. Metyrapone 59-69 proopiomelanocortin Homo sapiens 13-29 6307549-3 1983 In the early phase of the metyrapone experiments, plasma ACTH fell from 9.46 +/- 0.95 (SE) pmol/l at 08.00 h to 7.7 +/- 1.1 pmol/l at 09.00 h (P greater than 0.05) in the low-dose experiment, and from 7.0 +/- 1.6 pmol/l to 4.6 +/- 0.9 pmol/l (P less than 0.05) in the high-dose experiment. Metyrapone 26-36 proopiomelanocortin Homo sapiens 57-61 6308031-12 1983 A very close correlation was found between the rise of PS and ACTH levels at the end of metyrapone tests. Metyrapone 88-98 proopiomelanocortin Homo sapiens 62-66 6320567-4 1984 The hyperresponsiveness of plasma ACTH observed both in the metyrapone test and the lysine-vasopressin test was also ameliorated by treatment with trilostane. Metyrapone 60-70 proopiomelanocortin Homo sapiens 34-38 6307549-4 1983 A significant delayed increase of plasma ACTH secondary to the hypocortisolaemic stimulus was apparent in the high-dose experiment, in which plasma cortisol was maximally suppressed to 14 +/- 3 nmol/l at 13.00 h. No significant increase was observed in the low-dose experiment, the maximal suppression of plasma cortisol being 46 +/- 9 nmol/l at 14.00 h. The present data suggest dual effects of metyrapone on plasma ACTH: 1) a suppressive effect, the mechanism of which is not yet understood, and 2) the known increasing effect of "feed-back" stimulation, which seems to be very sensitive to alterations of plasma cortisol only at cortisol levels lower than about 50 nmol/l. Metyrapone 396-406 proopiomelanocortin Homo sapiens 41-45 6307549-5 1983 The suppressive effect of metyrapone may account for the frequently described inadequate response of plasma ACTH to metyrapone-induced hypocortisolaemia. Metyrapone 26-36 proopiomelanocortin Homo sapiens 108-112 6307549-5 1983 The suppressive effect of metyrapone may account for the frequently described inadequate response of plasma ACTH to metyrapone-induced hypocortisolaemia. Metyrapone 116-126 proopiomelanocortin Homo sapiens 108-112 6303868-0 1983 [The discrepancy between ACTH and 11-deoxycortisol levels in a single dose metyrapone test]. Metyrapone 75-85 proopiomelanocortin Homo sapiens 25-29 6306711-1 1983 Plasma ACTH levels after oral ingestion of 2 g metyrapone at 24.00 hours in six healthy subjects were higher after pretreatment with zimelidine (300 mg) in comparison to placebo. Metyrapone 47-57 proopiomelanocortin Homo sapiens 7-11 6245561-2 1980 In 32 subjects the hypothalamic-pituitary-adrenocortical (HPA) response to metyrapone was found to correlate significantly with the adrenocortical response to exogenous ACTH. Metyrapone 75-85 proopiomelanocortin Homo sapiens 169-173 6285792-3 1982 Plasma ACTH was low and remained so after LVD and metyrapone. Metyrapone 50-60 proopiomelanocortin Homo sapiens 7-11 6276646-5 1982 The diagnosis of isolated ACTH deficiency due to intrinsic pituitary disease is made unequivocally when all the following criteria are met: 1) low basal urinary 17-hydroxycorticosteroid (17-OHCS) levels with or without low basal plasma cortisol, 2) low or normal basal plasma ACTH, 3) stimulation of cortisol, 17-OHCS or both during prolonged ACTH administration, 4) lack of 17-OHCS elevation in response to metyrapone and 5) normal secretory indices of other pituitary hormones. Metyrapone 408-418 proopiomelanocortin Homo sapiens 26-30 6273512-4 1981 In the hormone assessment, basal cortisol and 17-hydroxycorticoids were normal and cortisol diurnal variation was near normal, but a dexamethasone suppression test and ACTH responses to metyrapone and insulin hypoglycemia were abnormal. Metyrapone 186-196 proopiomelanocortin Homo sapiens 168-172 6269918-2 1981 Thereafter plasma S, cortisol (F) and adrenocorticotropic hormone (ACTH) responses to metyrapone were investigated in 13 normal adult males and 39 patients with prostatic cancer. Metyrapone 86-96 proopiomelanocortin Homo sapiens 38-65 6269918-2 1981 Thereafter plasma S, cortisol (F) and adrenocorticotropic hormone (ACTH) responses to metyrapone were investigated in 13 normal adult males and 39 patients with prostatic cancer. Metyrapone 86-96 proopiomelanocortin Homo sapiens 67-71 6269918-15 1981 4) In case treated wih estrogens, plasma, S, F and ACTH responses to metyrapone were unchanged compared to normal adult males 2 approximately 4 weeks after discontinuation of the therapy, and this data suggested that estrogens had no inhibitory effect on the pituitary-adrenal axis. Metyrapone 69-79 proopiomelanocortin Homo sapiens 51-55 6269918-16 1981 However, in cases treated with progestational agents over a long-term period, plasma S and ACTH responses to metyrapone decreased slightly but returned to the normal range 2 approximately 4 weeks after discontinuation of the therapy. Metyrapone 109-119 proopiomelanocortin Homo sapiens 91-95 6273024-2 1981 Plasma ACTH concentrations following metyrapone were significantly lower in patients with pituitary disease with no evidence of anterior pituitary hormone deficiency (mean 90.0 +/- SD 63.9 ng/l) when compared with normal individuals (mean 182.5 +/- SD 14.1 ng/l, P leads than 0.01) but significantly greater than in patients with pituitary disease in whom a deficiency of one or more anterior pituitary hormones was demonstrated (mean 50.8 +/- SD 14.1 ng/l, P less than 0.01). Metyrapone 37-47 proopiomelanocortin Homo sapiens 7-11 6273024-3 1981 It is concluded that the short metyrapone test is a sensitive method of detecting minor degrees of impairment of the negative feedback control of aCTH secretion that would be unrecognized by conventional assessment by insulin-induced hypoglycaemia. Metyrapone 31-41 proopiomelanocortin Homo sapiens 146-150 6273024-4 1981 The clinical relevance of impaired ACTH release in response to a single dose of metyrapone in patients with pituitary tumours, in whom pituitary function is otherwise shown to be adequate, needs to be determined. Metyrapone 80-90 proopiomelanocortin Homo sapiens 35-39 6273833-0 1981 Response of ectopic prostatic ACTH production to metyrapone. Metyrapone 49-59 proopiomelanocortin Homo sapiens 30-34 6273022-2 1981 Neither patient showed any evidence of a tumour and both responded dramatically to treatment with metyrapone in that all abnormal clinical features disappeared, ACTH concentrations returned to normal and both patients showed prolonged remission after metyrapone treatment was stopped. Metyrapone 98-108 proopiomelanocortin Homo sapiens 161-165 6273022-5 1981 When these are reduced by metyrapone administration ACTH secretion falls in parallel and prolonged remission of disease may result. Metyrapone 26-36 proopiomelanocortin Homo sapiens 52-56 6257016-5 1981 The stimulation of ACTH secretion with metyrapone (750 mg perorally) significantly increased the mean plasma levels of 1-39 ACTH after 3 h (from 0.9 to 6.6 pmol/l) in 10 healthy individuals. Metyrapone 39-49 proopiomelanocortin Homo sapiens 19-23 6257016-5 1981 The stimulation of ACTH secretion with metyrapone (750 mg perorally) significantly increased the mean plasma levels of 1-39 ACTH after 3 h (from 0.9 to 6.6 pmol/l) in 10 healthy individuals. Metyrapone 39-49 proopiomelanocortin Homo sapiens 124-128 6253555-0 1980 Short-term kinetics of serum adrenal steroids and plasma ACTH after a single dose of metyrapone in man. Metyrapone 85-95 proopiomelanocortin Homo sapiens 57-61 6251560-0 1980 [ACTH response to 24 hours oral metyrapone test in normal children (author"s transl)]. Metyrapone 32-42 proopiomelanocortin Homo sapiens 1-5 6251560-1 1980 A study of ACTH response to orally given metyrapone were carried out with 32 normal subjects aged 18 months to 15. Metyrapone 41-51 proopiomelanocortin Homo sapiens 11-15 6251560-6 1980 Including these considerations, biological ACTH variability, and reproductibility of determinations, an abnormal response seems to be proved by plasma ACTH level at 8 after metyrapone < 100 pg/ml or/and delta ACTH < 70 pg. Metyrapone 173-183 proopiomelanocortin Homo sapiens 151-155 6251560-6 1980 Including these considerations, biological ACTH variability, and reproductibility of determinations, an abnormal response seems to be proved by plasma ACTH level at 8 after metyrapone < 100 pg/ml or/and delta ACTH < 70 pg. Metyrapone 173-183 proopiomelanocortin Homo sapiens 151-155 6251561-2 1980 Study of ACTH responsiveness to oral metyrapone and insulin hypoglycemia in children with repetitive nervous system manifestations (convulsions, coma, mental confusion apathy, tremor) has led to diagnosis of isolated ACTH deficiency in nine children within a three year period. Metyrapone 37-47 proopiomelanocortin Homo sapiens 9-13 6251561-2 1980 Study of ACTH responsiveness to oral metyrapone and insulin hypoglycemia in children with repetitive nervous system manifestations (convulsions, coma, mental confusion apathy, tremor) has led to diagnosis of isolated ACTH deficiency in nine children within a three year period. Metyrapone 37-47 proopiomelanocortin Homo sapiens 217-221 6303868-11 1983 This provides evidence for a discrepancy between plasma 11-deoxycortisol and ACTH responses in a single dose metyrapone test, as disclosed by the simultaneous administration of dopamine agonist or antagonist with metyrapone. Metyrapone 109-119 proopiomelanocortin Homo sapiens 77-81 6303868-11 1983 This provides evidence for a discrepancy between plasma 11-deoxycortisol and ACTH responses in a single dose metyrapone test, as disclosed by the simultaneous administration of dopamine agonist or antagonist with metyrapone. Metyrapone 213-223 proopiomelanocortin Homo sapiens 77-81 6273180-9 1981 When the steroid esters were injected after pretreatment with metyrapone, a definite suppression of plasma ACTH was noted after dexamethasone phosphate, but again, dexamethasone sulphate was ineffective. Metyrapone 62-72 proopiomelanocortin Homo sapiens 107-111 6252234-2 1980 She had high urinary free cortisol levels (711 micrograms/day) and a positive response to metyrapone and suppression with 8 mg dexamethasone, suggesting pituitary ACTH-dependent adrenocortical hyperfunction. Metyrapone 90-100 proopiomelanocortin Homo sapiens 163-167 6247589-6 1980 Deficit of ACTH release was demonstrated after the administration of metopyrone, ACTH and 0.1 UI insulin per kilogram of body weight to induce hypoglycemia. Metyrapone 69-79 proopiomelanocortin Homo sapiens 11-15 6276625-0 1980 Effects of cyproheptadine and metyrapone on ACTH and aldosterone concentrations in patients with Cushing"s disease: a preliminary report. Metyrapone 30-40 proopiomelanocortin Homo sapiens 44-48 7443728-7 1980 Increased beta-endorphin levels were found after various stress conditions in rat plasma, as well as after treatment with metyrapone and vasopressin. Metyrapone 122-132 proopiomelanocortin Homo sapiens 10-24 468983-4 1979 In subjects with intact hypothalamic-pituitary-adrenal axis, beta-EP was undetectable after dexamethasone and increased after metyrapone administration and insulin-induced hypoglycemia. Metyrapone 126-136 proopiomelanocortin Homo sapiens 61-68 225068-1 1979 Plasma ACTH levels in response to metyrapone and insulin hypoglycaemia were compared in subjects with normal pituitary-adrenal function. Metyrapone 34-44 proopiomelanocortin Homo sapiens 7-11 225068-2 1979 After a single dose of 2 g of metyrapone given with a snack at midnight, the ACTH level was 468 ng/l +/- 66 )SEM) at 07.30 h the next morning (mean increment approximately nine fold over normal morning values). Metyrapone 30-40 proopiomelanocortin Homo sapiens 77-81 225068-4 1979 Peak ACTH levels greater than 200 ng/l were achieved in twenty of twenty-one (95%) subjects after metyrapone and twenty of twenty-four (83%) after insulin. Metyrapone 98-108 proopiomelanocortin Homo sapiens 5-9 225068-6 1979 It is concluded that the short single-dose metyrapone test produces at least as strong and consistent a stimulus to ACTH release as the standard insulin-hypoglycaemia test in normal subjects. Metyrapone 43-53 proopiomelanocortin Homo sapiens 116-120 225068-8 1979 The short test has significant practical advantages over the classical metyrapone test, and provides a convenient and sensitive method of assessing the negative feedback ACTH control mechanism. Metyrapone 71-81 proopiomelanocortin Homo sapiens 170-174 219007-9 1979 This patient had diminished ACTH reserve, demonstrated by a subnormal response to metyrapone. Metyrapone 82-92 proopiomelanocortin Homo sapiens 28-32 225710-2 1979 Studies on control of ACTH secretion in these patients reveal: (a) that the episodic secretion of ACTH is similar to the normal; however, frequency and amplitude of the secretory episodes lack the normal circadian rhythm; (b) that ACTH release can be stimulated by vasopressin and metyrapone in a normal or above-normal manner; and (c) that it can be suppressed by large doses of corticosteroids. Metyrapone 281-291 proopiomelanocortin Homo sapiens 22-26 7354720-6 1980 Correlations of free DOC and aldosterone excretion with free cortisol excretion, and their responses to the administration of metyrapone and dexamethasone were compatible with ACTH dependency in adrenal hyperplasia, autonomous production of steroids in adrenal adenomas and a chaotic steroidogenesis in adrenal carcinoma. Metyrapone 126-136 proopiomelanocortin Homo sapiens 176-180 219030-0 1978 Presence of immunoreactive beta-endorphin in normal human plasma: a concomitant release of beta-endorphin with adrenocorticotropin after metyrapone administration. Metyrapone 137-147 proopiomelanocortin Homo sapiens 91-105 219030-2 1978 The basal plasma level of beta-endorphin was 5.8 +/- 1.1 pg/ml (mean +/- SE, n = 5), which rose significantly to the level of 48.9 +/- 3.8 pg/ml after a single oral dose (30 mg/kg of body wt) of metyrapone administration (P less than 0.001). Metyrapone 195-205 proopiomelanocortin Homo sapiens 26-40 219030-3 1978 Plasma ACTH levels also increased from the mean basal level of 73 +/- 4 pg/ml to 269 +/- 41 pg/ml after metyrapone administration. Metyrapone 104-114 proopiomelanocortin Homo sapiens 7-11 673022-8 1978 beta-Endorphin levels in adrenalectomized rats and in animals chronically treated with the cortisol synthesis blocker metyrapone were found to be markedly increased (about 7-fold). Metyrapone 118-128 proopiomelanocortin Homo sapiens 0-14 225710-2 1979 Studies on control of ACTH secretion in these patients reveal: (a) that the episodic secretion of ACTH is similar to the normal; however, frequency and amplitude of the secretory episodes lack the normal circadian rhythm; (b) that ACTH release can be stimulated by vasopressin and metyrapone in a normal or above-normal manner; and (c) that it can be suppressed by large doses of corticosteroids. Metyrapone 281-291 proopiomelanocortin Homo sapiens 98-102 225710-2 1979 Studies on control of ACTH secretion in these patients reveal: (a) that the episodic secretion of ACTH is similar to the normal; however, frequency and amplitude of the secretory episodes lack the normal circadian rhythm; (b) that ACTH release can be stimulated by vasopressin and metyrapone in a normal or above-normal manner; and (c) that it can be suppressed by large doses of corticosteroids. Metyrapone 281-291 proopiomelanocortin Homo sapiens 98-102 184633-2 1976 Elevated plasma immunoreactive ACTH and cortisol were partially suppressed by intravenous dexamethasone, appreciably raised by lysine vasopressin, and urinary excretion of 17-oxogenic steroids slightly elevated by metyrapone. Metyrapone 214-224 proopiomelanocortin Homo sapiens 31-35 1262443-1 1976 In a patient with pituitary ACTH-dependent adrenal hyperplasia (AH), the standard oral metyrapone test resulted in a decrease in "apparent 11beta-hydroxylase activity" (-48%) accompanied by an increase in "apparent cholesterol cleavage activity" (+318%). Metyrapone 87-97 proopiomelanocortin Homo sapiens 28-32 1262443-3 1976 The inhibition of cholesterol cleavage by metyrapone (26 and 62%, at 0.1 and 1.0 mM concentrations, respectively) was also demonstrable in adrenal mitochondria from a patient with hypercorticism resulting from an ACTH-independent adrenal adenoman (AA). Metyrapone 42-52 proopiomelanocortin Homo sapiens 213-217 1262443-4 1976 Metyrapone administration to AA resulted in a significant depression of both 11beta-hydroxylase (-62%) and cholesterol cleavage (-36%) "apparent activities"; when metyrapone and ACTH were given together to this patient, however, only 11beta-hydroxylase "apparent activity" diminished (-26%), while cholesterol cleavage "apparent activity" was greatly augmented (+231%), thereby simulating the results of the standard metyrapone test in AH. Metyrapone 0-10 proopiomelanocortin Homo sapiens 178-182 1262443-6 1976 Since ACTH has a major stimulatory effect on cholesterol cleavage but not on 11beta-hydroxylation, the outcome of metyrapone administration is thus determined by whether a change in ACTH level ensues: while 11beta-hydroxylation is inhibited by metyrapone under any circumstances, total steroid output rises when a compensatory ACTH increase overcomes metyrapone inhibition of cholesterol conversion into pregnenolone and falls when metyrapone inhibition of this reaction is unopposed. Metyrapone 114-124 proopiomelanocortin Homo sapiens 182-186 1262443-6 1976 Since ACTH has a major stimulatory effect on cholesterol cleavage but not on 11beta-hydroxylation, the outcome of metyrapone administration is thus determined by whether a change in ACTH level ensues: while 11beta-hydroxylation is inhibited by metyrapone under any circumstances, total steroid output rises when a compensatory ACTH increase overcomes metyrapone inhibition of cholesterol conversion into pregnenolone and falls when metyrapone inhibition of this reaction is unopposed. Metyrapone 114-124 proopiomelanocortin Homo sapiens 182-186 173735-5 1975 However, metyrapone infusion caused a significant increase of both ACTH and beta-MSH levels, and frequent blood sampling revealed that both hormones were secreted episodically, and that peaks generally coincided with each other. Metyrapone 9-19 proopiomelanocortin Homo sapiens 67-71 173735-5 1975 However, metyrapone infusion caused a significant increase of both ACTH and beta-MSH levels, and frequent blood sampling revealed that both hormones were secreted episodically, and that peaks generally coincided with each other. Metyrapone 9-19 proopiomelanocortin Homo sapiens 76-84 173237-3 1975 In hypopituitarism, metopirone ACTH levels are low and unchanged during the tests. Metyrapone 20-30 proopiomelanocortin Homo sapiens 31-35 168228-0 1975 Inhibition of ACTH response to oral and intravenous metyrapone by antiserotoninergic treatment in man. Metyrapone 52-62 proopiomelanocortin Homo sapiens 14-18 168228-2 1975 In 3 additional women, the effects of methysergide, another antiserotoninergic drug, on the plasma ACTH rise induced by oral metyrapone, were evaluated. Metyrapone 125-135 proopiomelanocortin Homo sapiens 99-103 168228-3 1975 A significant lowering of the plasma ACTH levels attained after either oral or iv metyrapone was observed following metergoline administration: 149+/-64.3 vs 239+/-49.1 pg/ml (mean peak values), P less than 0.05 in the oral test and 331+/-19.7 vs 221+/-19.5 pg/ml, P less than 0.02 in the iv test. Metyrapone 82-92 proopiomelanocortin Homo sapiens 37-41 168228-7 1975 A decrease, however not statistically significant, of the metyrapone-induced plasma ACTH elevation occured after methysergide administration: 421+/-150.7 vs 344+/-135.1 pg/ml. Metyrapone 58-68 proopiomelanocortin Homo sapiens 84-88 168228-8 1975 These results can be interpreted as indicating that antiserotoninergic treatment caused an inhibition of hypophysial ACTH release in response to metyrapone. Metyrapone 145-155 proopiomelanocortin Homo sapiens 117-121 4285288-0 1965 [Determination of ACTH reserve in endocrinologic and cirrhotic patients by the metopirone test]. Metyrapone 79-89 proopiomelanocortin Homo sapiens 18-22 165367-7 1975 Of the various tests which indirectly assess the potential for ACTH secretion, the use of metyrapone is most helpful. Metyrapone 90-100 proopiomelanocortin Homo sapiens 63-67 169169-2 1975 Two patients in Group A with normal circadian rhythm of serum corticoid levels exhibited abnormal rhythm in ACTH responsiveness to metyrapone. Metyrapone 131-141 proopiomelanocortin Homo sapiens 108-112 169169-3 1975 In contrast, 2 other patients in Group A with normal rhythm in ACTH responsiveness to metyrapone exhibited abnormal circadian rhythms of serum corticoid levels. Metyrapone 86-96 proopiomelanocortin Homo sapiens 63-67 169169-4 1975 In spite of the disturbed circadian rhythm of serum corticoid levels, 2 patients in Group B showed normal rhythm in ACTH responsiveness to metyrapone. Metyrapone 139-149 proopiomelanocortin Homo sapiens 116-120 172298-0 1975 Circadian rhythm of urinary 17-hydroxycorticosteroids during metyrapone-induced ACTH release in normal subjects. Metyrapone 61-71 proopiomelanocortin Homo sapiens 80-84 172298-8 1975 The results suggest a time-limited action of metyrapone upon the pituitary-adrenal axis, since the increased excretion of 17-OHCS seems essentially accounted for by an exaggerated impulsive phase of ACTH secretion during the early morning hours. Metyrapone 45-55 proopiomelanocortin Homo sapiens 199-203 163970-9 1975 Metyrapone induced a normal ACTH rise, but at abnormal times. Metyrapone 0-10 proopiomelanocortin Homo sapiens 28-32 163970-19 1975 However, even when pituitary tumors occur, ACTH levels can be altered by metyrapone, dexamethasone and LVP. Metyrapone 73-83 proopiomelanocortin Homo sapiens 43-47 4318790-1 1970 Negative effect on ACTH reserve in man by metyrapone test. Metyrapone 42-52 proopiomelanocortin Homo sapiens 19-23 7364929-5 1980 In one of the healthy subjects who had exhibited diminished response to metyrapone on hGH, measurement of plasma ACTH levels demonstrated a lower rise after the administration of the drug. Metyrapone 72-82 proopiomelanocortin Homo sapiens 113-117 4350859-0 1973 Modification of high temperature and ACTH induced immunodepression by metyrapone. Metyrapone 70-80 proopiomelanocortin Homo sapiens 37-41 4302180-8 1968 In a group of subjects showing frequent spiking of plasma 17-OHCS concentrations throughout the day parallel spiking of plasma ACTH as well was generally observed.Metyrapone produced marked increases in plasma ACTH within 24 hr in all cases and generally within 3-6 hr except when started late in the day. Metyrapone 163-173 proopiomelanocortin Homo sapiens 127-131 4302180-8 1968 In a group of subjects showing frequent spiking of plasma 17-OHCS concentrations throughout the day parallel spiking of plasma ACTH as well was generally observed.Metyrapone produced marked increases in plasma ACTH within 24 hr in all cases and generally within 3-6 hr except when started late in the day. Metyrapone 163-173 proopiomelanocortin Homo sapiens 210-214 4302180-9 1968 Dexamethasone brought about a persistent reduction in plasma ACTH in a patient under continued treatment with metyrapone.Hypoglycemia, electroshock, surgery under general anesthesia, histalog and vasopressin administration were usually followed by significant increases in plasma ACTH concentration. Metyrapone 110-120 proopiomelanocortin Homo sapiens 61-65 4302180-9 1968 Dexamethasone brought about a persistent reduction in plasma ACTH in a patient under continued treatment with metyrapone.Hypoglycemia, electroshock, surgery under general anesthesia, histalog and vasopressin administration were usually followed by significant increases in plasma ACTH concentration. Metyrapone 110-120 proopiomelanocortin Homo sapiens 280-284 4300336-0 1968 [Test for ACTH-secreting capacity using synthetic lysine-8-vasopressin and metopirone]. Metyrapone 75-85 proopiomelanocortin Homo sapiens 10-14 4294158-0 1966 [Evaluation of the secretory capacity of ACTH by the pituitary with metyrapone in patients with amenorrhea]. Metyrapone 68-78 proopiomelanocortin Homo sapiens 41-45 4285347-0 1965 [Preliminary report: determination of the pituitary ACTH reserve using metyrapone, based on the measurement of urinary levels of 11-desoxy-17, 21-dihydroxycorticosteroids (11-DOCS)]. Metyrapone 71-81 proopiomelanocortin Homo sapiens 52-56 13946599-0 1963 [On the behavior of endogenous ACTH activity in human plasma after enzymatic block of cortisol synthesis with metopirone (SU 4885). Metyrapone 110-120 proopiomelanocortin Homo sapiens 31-35 14456817-0 1961 [Determination of hypophysial ACTH reserve with SU-4885 (metopiron)]. Metyrapone 48-55 proopiomelanocortin Homo sapiens 30-34 14456817-0 1961 [Determination of hypophysial ACTH reserve with SU-4885 (metopiron)]. Metyrapone 57-66 proopiomelanocortin Homo sapiens 30-34 14453335-0 1961 Pituitary corticotrophin (ACTH) production in rheumatoid arthritis tested indirectly with Metopiron (Su 4885). Metyrapone 90-99 proopiomelanocortin Homo sapiens 26-30 32168466-13 2020 A preliminary diagnosis of ectopic ACTH secretion from the known right-sided phaeochromocytoma was made and he was started on metyrapone and insulin. Metyrapone 126-136 proopiomelanocortin Homo sapiens 35-39 34061117-4 2021 The initiation of metyrapone paradoxically decreased plasma adrenocorticotropic hormone (ACTH) levels and suppressed cortisol levels. Metyrapone 18-28 proopiomelanocortin Homo sapiens 60-87 34061117-4 2021 The initiation of metyrapone paradoxically decreased plasma adrenocorticotropic hormone (ACTH) levels and suppressed cortisol levels. Metyrapone 18-28 proopiomelanocortin Homo sapiens 89-93 32921682-4 2021 Metyrapone was used to suppress cortisol production and resulted in decreased levels of ACTH and cortisol. Metyrapone 0-10 proopiomelanocortin Homo sapiens 88-92 4292513-0 1967 [Pituitary functional reserve for ACTH excretion in children after the administration of metyrapone]. Metyrapone 89-99 proopiomelanocortin Homo sapiens 34-38 29760304-0 2018 Metyrapone-responsive ectopic ACTH-secreting pheochromocytoma with a vicious cycle via a glucocorticoid-driven positive-feedback mechanism. Metyrapone 0-10 proopiomelanocortin Homo sapiens 30-34 30561712-8 2019 Daily metyrapone therapy decreased her plasma cortisol and ACTH levels during every hypercortisolemic phase. Metyrapone 6-16 proopiomelanocortin Homo sapiens 59-63 30561712-11 2019 Treatment using a combination of dexamethasone and metyrapone did not increase plasma ACTH or cortisol level and successfully prevented development of ACTH-dependent hypercortisolism. Metyrapone 51-61 proopiomelanocortin Homo sapiens 151-155 29760304-8 2018 After metyrapone administration, not only serum cortisol but also plasma ACTH levels were exponentially decreased almost in parallel, suggesting a glucocorticoid-driven positive-feedback regulation in this rapidly exacerbated ectopic ACTH-producing pheochromocytoma. Metyrapone 6-16 proopiomelanocortin Homo sapiens 73-77 29760304-8 2018 After metyrapone administration, not only serum cortisol but also plasma ACTH levels were exponentially decreased almost in parallel, suggesting a glucocorticoid-driven positive-feedback regulation in this rapidly exacerbated ectopic ACTH-producing pheochromocytoma. Metyrapone 6-16 proopiomelanocortin Homo sapiens 234-238 29268182-3 2018 Metyrapone blocks cortisol synthesis, removing negative feedback, and increases the release of hypothalamic CRF and pituitary adrenocorticotropic hormone (ACTH). Metyrapone 0-10 proopiomelanocortin Homo sapiens 155-159 29587720-0 2018 Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review. Metyrapone 97-107 proopiomelanocortin Homo sapiens 12-39 29587720-0 2018 Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review. Metyrapone 97-107 proopiomelanocortin Homo sapiens 41-45 29587720-0 2018 Spontaneous adrenocorticotropic hormone (ACTH) normalisation due to tumour regression induced by metyrapone in a patient with ectopic ACTH syndrome: case report and literature review. Metyrapone 97-107 proopiomelanocortin Homo sapiens 134-138 29587720-3 2018 We presented a case of EAS in which ACTH production by a lung tumour was reduced by metyrapone (MTP) and also reviewed previous cases of ectopic ACTH production suppressed via steroidogenesis inhibition. Metyrapone 84-94 proopiomelanocortin Homo sapiens 36-40 29587720-3 2018 We presented a case of EAS in which ACTH production by a lung tumour was reduced by metyrapone (MTP) and also reviewed previous cases of ectopic ACTH production suppressed via steroidogenesis inhibition. Metyrapone 96-99 proopiomelanocortin Homo sapiens 36-40 29587720-11 2018 ACTH levels and cortisol and UFC levels were normalised and the ACTH-producing lung tumour was ablated after MTP treatment. Metyrapone 109-112 proopiomelanocortin Homo sapiens 64-68 29587720-16 2018 The patients were treated with ketoconazole (KTZ) and/or MTP and exhibited ACTH and cortisol/UFC suppression, but tumour regression was observed only in our case. Metyrapone 57-60 proopiomelanocortin Homo sapiens 75-79 29587720-17 2018 CONCLUSION: MTP and/or KTZ may reduce ACTH and cortisol production. Metyrapone 12-15 proopiomelanocortin Homo sapiens 38-42 29268182-6 2018 Metyrapone resulted in a greater increase in ACTH and greater decreases in cortisol and delta spectral power sleep in PTSD subjects compared to controls, and a greater increase in ACTH in women compared to men. Metyrapone 0-10 proopiomelanocortin Homo sapiens 45-49 29268182-6 2018 Metyrapone resulted in a greater increase in ACTH and greater decreases in cortisol and delta spectral power sleep in PTSD subjects compared to controls, and a greater increase in ACTH in women compared to men. Metyrapone 0-10 proopiomelanocortin Homo sapiens 180-184 28277127-0 2017 A successful case of pregnancy in a woman with ACTH-independent Cushing"s syndrome treated with ketoconazole and metyrapone. Metyrapone 113-123 proopiomelanocortin Homo sapiens 47-51 27750352-0 2017 Dynamics of Adrenocorticotropin after Application of Metyrapone. Metyrapone 53-63 proopiomelanocortin Homo sapiens 12-31 28328532-8 2017 Due to unsuccessful therapy with ketoconazole and resistance to antihypertensive medications [blood pressure (BP) 210/160 mmHg], metyrapone was administered, which controlled her ACTH and cortisol levels in the normal range. Metyrapone 129-139 proopiomelanocortin Homo sapiens 179-183 27750352-1 2017 Purpose: To investigate the kinetics of adrenocorticotropin (ACTH) following oral metyrapone administration and describe differences between ACTH-deficient and non-ACTH-deficient subjects. Metyrapone 82-92 proopiomelanocortin Homo sapiens 40-59 27750352-1 2017 Purpose: To investigate the kinetics of adrenocorticotropin (ACTH) following oral metyrapone administration and describe differences between ACTH-deficient and non-ACTH-deficient subjects. Metyrapone 82-92 proopiomelanocortin Homo sapiens 61-65 27750352-6 2017 Results: A significant rise in ACTH concentration compared to basal values was found at 60 and 120 min following oral metyrapone administration. Metyrapone 118-128 proopiomelanocortin Homo sapiens 31-35 27750352-9 2017 Conclusion: In contrast to previous reports, we found a significant rise in ACTH concentration as soon as one hour after oral metyrapone administration. Metyrapone 126-136 proopiomelanocortin Homo sapiens 76-80 27750352-11 2017 Further studies are needed to investigate this finding as a potential basis for a ACTH-based metyrapone short test protocol. Metyrapone 93-103 proopiomelanocortin Homo sapiens 82-86 26859587-0 2015 The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Metyrapone 25-35 proopiomelanocortin Homo sapiens 82-86 24416602-6 2013 Long-term treatment with metyrapone is usually discouraged due to the contradictory increase in ACTH production, acne, hirsutism, hyperkalemia, edema, and other mineralocorticoid effects. Metyrapone 25-35 proopiomelanocortin Homo sapiens 96-100 22038492-0 2012 Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia. Metyrapone 47-57 proopiomelanocortin Homo sapiens 88-92 26700559-6 2016 Ectopic ACTH secretion and catecholamine production were blocked by metyrapone treatment, whereas dexamethasone paradoxically increased ACTH secretion. Metyrapone 68-78 proopiomelanocortin Homo sapiens 8-12 25450859-2 2015 Long-term use of metyrapone is limited by hirsutism and hypertension and escape because of increased ACTH levels. Metyrapone 17-27 proopiomelanocortin Homo sapiens 101-105 25799272-5 2015 After metyrapone administration ACTH was significantly enhanced, while overall nocturnal cortisol secretion remained largely unchanged. Metyrapone 6-16 proopiomelanocortin Homo sapiens 32-36 24952092-4 2014 OBJECTIVE: The present study examined the effects of sex and PTSD on adrenocorticotropic hormone (ACTH), progesterone, and allopregnanolone responses to metyrapone and whether progesterone and allopregnanolone reactivity could affect the ACTH response in PTSD. Metyrapone 153-163 proopiomelanocortin Homo sapiens 69-96 24952092-6 2014 RESULTS: The increase in ACTH response to metyrapone was higher in PTSD subjects compared to controls and in women compared to men. Metyrapone 42-52 proopiomelanocortin Homo sapiens 25-29 24952092-9 2014 CONCLUSIONS: Our findings of increased ACTH to metyrapone in PTSD and in women may reflect heightened hypothalamic CRF hypersecretion. Metyrapone 47-57 proopiomelanocortin Homo sapiens 39-43 21507151-0 2013 Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. Metyrapone 151-161 proopiomelanocortin Homo sapiens 104-131 21507151-6 2013 The 118G allele blunted the adrenocorticotropic hormone (ACTH) response to metyrapone. Metyrapone 75-85 proopiomelanocortin Homo sapiens 28-55 21507151-6 2013 The 118G allele blunted the adrenocorticotropic hormone (ACTH) response to metyrapone. Metyrapone 75-85 proopiomelanocortin Homo sapiens 57-61 22211368-3 2012 RESULTS: Under metyrapone, the increases of plasma adrenocorticotropic hormone (ACTH) concentrations and of basal and pulsatile ACTH secretion were not exaggerated in hypercortisolemic depressed patients compared with control subjects. Metyrapone 15-25 proopiomelanocortin Homo sapiens 51-78 22211368-3 2012 RESULTS: Under metyrapone, the increases of plasma adrenocorticotropic hormone (ACTH) concentrations and of basal and pulsatile ACTH secretion were not exaggerated in hypercortisolemic depressed patients compared with control subjects. Metyrapone 15-25 proopiomelanocortin Homo sapiens 80-84 22211368-3 2012 RESULTS: Under metyrapone, the increases of plasma adrenocorticotropic hormone (ACTH) concentrations and of basal and pulsatile ACTH secretion were not exaggerated in hypercortisolemic depressed patients compared with control subjects. Metyrapone 15-25 proopiomelanocortin Homo sapiens 128-132